Table 2: Chimerism analysis in patients according to ATG administration.
| Characteristic | ATG+; n = 11 |
Non-ATG; n = 11 |
P |
|---|---|---|---|
| Patients (%) with CDC at day +28 (%) | 91% | 73% | 0.03a |
| Patients (%) with CDC at day +56 | 80% | 73% | 0.5 |
| Patients (%) with CDC at day +100 | 88% | 90% | 0.7 |
| Patients (%) with CDC at day +365 Patients (%) with CDC at the end of observation |
71% 82% |
89% 82% |
0.1 - |
ATG: Anti-Thymocyte Globulin; CDC: Complete Donor Chimerism; aSignificant, P value < 0.05.